JPMorgan Chase & Co. set a €70.00 ($81.40) target price on Bayer (FRA:BAYN) in a research report sent to investors on Monday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.
BAYN has been the subject of a number of other reports. Baader Bank set a €123.00 ($143.02) price objective on shares of Bayer and gave the stock a buy rating in a research report on Thursday, June 27th. Kepler Capital Markets set a €70.00 ($81.40) price objective on shares of Bayer and gave the stock a neutral rating in a research report on Thursday, June 27th. Deutsche Bank reduced their price objective on shares of Xilinx from $125.00 to $120.00 and set a hold rating for the company in a research report on Thursday, April 25th. DZ Bank upgraded shares of Telefonica from a hold rating to a buy rating in a research report on Tuesday, May 14th. Finally, Barclays upped their price objective on shares of Intuit from $225.00 to $237.00 and gave the stock an equal weight rating in a research report on Friday, May 24th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and an average price target of €80.67 ($93.81).
BAYN opened at €59.76 ($69.49) on Monday. The company has a fifty day moving average price of €56.55. Bayer has a 1 year low of €91.58 ($106.49) and a 1 year high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Further Reading: Options Trading – Understanding Strike Price
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.